Justin Trojanowski Acquires 7,500 Shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) Stock

Tempest Therapeutics, Inc. (NASDAQ:TPST) insider Justin Trojanowski purchased 7,500 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was bought at an average price of $2.16 per share, with a total value of $16,200.00. Following the acquisition, the insider now directly owns 22,168 shares in the company, valued at $47,882.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Tempest Therapeutics Price Performance

NASDAQ:TPST opened at $2.11 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.13 and a current ratio of 3.13. The firm has a 50-day moving average price of $3.06 and a two-hundred day moving average price of $3.62. Tempest Therapeutics, Inc. has a twelve month low of $0.17 and a twelve month high of $9.77.

Tempest Therapeutics (NASDAQ:TPST) last posted its earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.08. Analysts expect that Tempest Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Scotiabank assumed coverage on shares of Tempest Therapeutics in a report on Thursday, March 14th. They issued a “sector outperform” rating and a $13.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $8.00 price target on shares of Tempest Therapeutics in a report on Friday, June 21st. HC Wainwright reiterated a “buy” rating and issued a $47.00 price target on shares of Tempest Therapeutics in a report on Thursday, June 20th. Finally, William Blair restated an “outperform” rating on shares of Tempest Therapeutics in a report on Wednesday, March 20th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $20.75.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. MayTech Global Investments LLC purchased a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics makes up about 0.0% of MayTech Global Investments LLC’s holdings, making the stock its 29th biggest holding. MayTech Global Investments LLC owned approximately 0.05% of Tempest Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.